NasdaqGS:RVMDBiotechs
First-in-Human RMC-5127 Trial Could Be A Game Changer For Revolution Medicines (RVMD)
Revolution Medicines recently dosed the first patient in its first-in-human trial of RMC-5127, an open-label study assessing safety, tolerability, pharmacokinetics and early antitumor activity in RAS G12V-mutated solid tumors that have progressed after standard therapies.
This marks a key pipeline milestone targeting RAS G12V, the second most common driver of RAS-addicted cancers in the US, affecting roughly 48,000 patients annually.
We will now examine how initiating first-in-human testing...